NO.	compound_name	IUPAC_name	SMILES	CID	logBB	BBB+/BBB-	Inchi	threshold	reference	group	comments
1	acetyl-d-carnitine	(3S)-3-acetyloxy-4-(trimethylazaniumyl)butanoate	CC(=O)O[C@@H](CC(=O)[O-])C[N+](C)(C)C	18230		BBB+	InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m0/s1		DrugBank	E	DrugBank
2	Melatonin	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	896		BBB+	InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)		DrugBank	E	DrugBank
3	N-Acetyl-L-leucine	(2S)-2-acetamido-4-methylpentanoic acid	CC(=O)N[C@@H](CC(C)C)C(=O)O	70912		BBB+	InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1		DrugBank	E	DrugBank
4	amantadine	adamantan-1-amine	N[C@]12C[C@H]3C[C@H](C[C@H](C3)C1)C2	2130		BBB+	InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2/t7-,8+,9-,10-		DrugBank	E	DrugBank
5	Aramisulpride	4-amino-N-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide	CCN1CCC[C@@H]1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC	5746246		BBB+	InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m1/s1		DrugBank	E	DrugBank
6	SCHEMBL40777	(1S)-1-[(1R,2R,4R)-2-bicyclo[2.2.1]hept-5-enyl]-1-phenyl-3-piperidin-1-ylpropan-1-ol	O[C@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2	12149109		BBB+	InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2/t17-,18+,20-,21-/m1/s1		DrugBank	E	DrugBank
7	Levobupivacaine	(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	92253		BBB+	InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1		DrugBank	E	DrugBank
8	107220-27-9	(2R,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]	C[C@@H]1O[C@]2(CS1)CN1CCC2CC1	11041760		BBB+	InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10+/m1/s1		DrugBank	E	DrugBank
9	chlordiazepoxide	7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine	C/N=C1/CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1	2712		BBB+	InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3/b18-15-		DrugBank	E	DrugBank
10	Cloxazolam, (S)-	(11bS)-10-chloro-11b-(2-chlorophenyl)-2,3,5,7-tetrahydro-[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6-one	O=C1CN2CCO[C@]2(c2ccccc2Cl)c2cc(Cl)ccc2N1	25271643		BBB+	InChI=1S/C17H14Cl2N2O2/c18-11-5-6-15-13(9-11)17(12-3-1-2-4-14(12)19)21(7-8-23-17)10-16(22)20-15/h1-6,9H,7-8,10H2,(H,20,22)/t17-/m1/s1		DrugBank	E	DrugBank
11	diflunisal	5-(2,4-difluorophenyl)-2-hydroxybenzoic acid	O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O	3059		BBB+	InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)		DrugBank	E	DrugBank
12	FONAZINE, (R)-	10-[(2R)-2-(dimethylamino)propyl]-N,N-dimethylphenothiazine-2-sulfonamide	C[C@H](CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C	76960728		BBB+	InChI=1S/C19H25N3O2S2/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5/h6-12,14H,13H2,1-5H3/t14-/m1/s1		DrugBank	E	DrugBank
13	disulfiram	diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate	CCN(CC)C(=S)SSC(=S)N(CC)CC	3117		BBB+	InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3		DrugBank	E	DrugBank
14	Levofenfluramine	(2R)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine	CCN[C@H](C)Cc1cccc(C(F)(F)F)c1	65801		BBB+	InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3/t9-/m1/s1		DrugBank	E	DrugBank
15	FLOCTAFENINE, (R)-	[(2R)-2,3-dihydroxypropyl] 2-[[8-(trifluoromethyl)quinolin-4-yl]amino]benzoate	O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2c(C(F)(F)F)cccc12	76958517		BBB+	InChI=1S/C20H17F3N2O4/c21-20(22,23)15-6-3-5-13-17(8-9-24-18(13)15)25-16-7-2-1-4-14(16)19(28)29-11-12(27)10-26/h1-9,12,26-27H,10-11H2,(H,24,25)/t12-/m1/s1		DrugBank	E	DrugBank
16	Glafenine, (R)-	[(2R)-2,3-dihydroxypropyl] 2-[(7-chloroquinolin-4-yl)amino]benzoate	O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12	969495		BBB+	InChI=1S/C19H17ClN2O4/c20-12-5-6-14-17(7-8-21-18(14)9-12)22-16-4-2-1-3-15(16)19(25)26-11-13(24)10-23/h1-9,13,23-24H,10-11H2,(H,21,22)/t13-/m1/s1		DrugBank	E	DrugBank
17	maprotiline	N-methyl-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-1-amine	CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12	4011		BBB+	InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3/t15-,20+		DrugBank	E	DrugBank
18	Mazaticol	[(1R,3R,5R)-6,6,9-trimethyl-9-azabicyclo[3.3.1]nonan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate	CN1[C@@H]2CCC(C)(C)[C@H]1C[C@H](OC(=O)C(O)(c1cccs1)c1cccs1)C2	68667		BBB+	InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16-/m1/s1		DrugBank	E	DrugBank
19	(3R,5S)-3,5-dimethyl-1-adamantanamine	(3S,5R)-3,5-dimethyladamantan-1-amine	C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2	1263681		BBB+	InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3/t9-,10+,11-,12-		DrugBank	E	DrugBank
20	D-mepivacaine	(2R)-N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide	Cc1cccc(C)c1NC(=O)[C@H]1CCCCN1C	6918904		BBB+	InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)/t13-/m1/s1		DrugBank	E	DrugBank
21	Levomethadone	(6R)-6-(dimethylamino)-4,4-diphenylheptan-3-one	CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1	22267		BBB+	InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m1/s1		DrugBank	E	DrugBank
22	(R)-Methixene	(3R)-1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine	CN1CCC[C@H](CC2c3ccccc3Sc3ccccc32)C1	44163540		BBB+	InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3/t15-/m1/s1		DrugBank	E	DrugBank
23	Modafinil, (+)-	2-[(S)-benzhydrylsulfinyl]acetamide	NC(=O)C[S@](=O)C(c1ccccc1)c1ccccc1	11173366		BBB+	InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m0/s1		DrugBank	E	DrugBank
24	(R)-mosapramine	(8aR)-1'-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]spiro[1,5,6,7,8,8a-hexahydroimidazo[1,2-a]pyridine-3,4'-piperidine]-2-one	O=C1N[C@H]2CCCCN2C12CCN(CCCN1c3ccccc3CCc3ccc(Cl)cc31)CC2	12831242		BBB+	InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)/t26-/m1/s1		DrugBank	E	DrugBank
25	NEOSTIGMINE	[3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium	CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1	4456		BBB+	InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1		DrugBank	E	DrugBank
26	nifenazone	N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)pyridine-3-carboxamide	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	4487		BBB+	InChI=1S/C17H16N4O2/c1-12-15(19-16(22)13-7-6-10-18-11-13)17(23)21(20(12)2)14-8-4-3-5-9-14/h3-11H,1-2H3,(H,19,22)		DrugBank	E	DrugBank
27	phenacetin	N-(4-ethoxyphenyl)acetamide	CCOc1ccc(NC(C)=O)cc1	4754		BBB+	InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)		DrugBank	E	DrugBank
28	14289-32-8	(2R)-N-(2-methylphenyl)-2-(propylamino)propanamide	CCCN[C@H](C)C(=O)Nc1ccccc1C	12444990		BBB+	InChI=1S/C13H20N2O/c1-4-9-14-11(3)13(16)15-12-8-6-5-7-10(12)2/h5-8,11,14H,4,9H2,1-3H3,(H,15,16)/t11-/m1/s1		DrugBank	E	DrugBank
29	propentofylline	3-methyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione	CCCn1cnc2c1c(=O)n(CCCCC(C)=O)c(=O)n2C	4938		BBB+	InChI=1S/C15H22N4O3/c1-4-8-18-10-16-13-12(18)14(21)19(15(22)17(13)3)9-6-5-7-11(2)20/h10H,4-9H2,1-3H3		DrugBank	E	DrugBank
30	pyridostigmine	(1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate	CN(C)C(=O)Oc1ccc[n+](C)c1	4991		BBB+	InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1		DrugBank	E	DrugBank
31	salicylamide	2-hydroxybenzamide	NC(=O)c1ccccc1O	5147		BBB+	InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)		DrugBank	E	DrugBank
32	Salsalate	2-(2-hydroxybenzoyl)oxybenzoic acid	O=C(Oc1ccccc1C(=O)O)c1ccccc1O	5161		BBB+	InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)		DrugBank	E	DrugBank
33	(+)-Scopolamine	[(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2R)-3-hydroxy-2-phenylpropanoate	CN1[C@@H]2C[C@H](OC(=O)[C@@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12	673473		BBB+	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13+,14-,15+,16-/m0/s1		DrugBank	E	DrugBank
34	tetracaine	2-(dimethylamino)ethyl 4-(butylamino)benzoate	CCCCNc1ccc(C(=O)OCCN(C)C)cc1	5411		BBB+	InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3		DrugBank	E	DrugBank
35	triclofos	2,2,2-trichloroethyl dihydrogen phosphate	O=P(O)(O)OCC(Cl)(Cl)Cl	5563		BBB+	InChI=1S/C2H4Cl3O4P/c3-2(4,5)1-9-10(6,7)8/h1H2,(H2,6,7,8)		DrugBank	E	DrugBank
36	(R)-trihexyphenidyl	(1R)-1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol	O[C@@](CCN1CCCCC1)(c1ccccc1)C1CCCCC1	207843		BBB+	InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2/t20-/m0/s1		DrugBank	E	DrugBank
37	pilocarpine	(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one	CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C	5910		BBB+	InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1		DrugBank	E	DrugBank
38	3,4-DIAMINOPYRIDINE	pyridine-3,4-diamine	Nc1ccncc1N	5918		BBB+	InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)		DrugBank	E	DrugBank
39	(R)-mebutamate	[(3R)-2-(carbamoyloxymethyl)-2,3-dimethylpentyl] carbamate	CC[C@@H](C)C(C)(COC(N)=O)COC(N)=O	57066553		BBB+	InChI=1S/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)/t7-/m1/s1		DrugBank	E	DrugBank
40	Butanoic acid, 2-amino-, (2S)-	(2S)-2-aminobutanoic acid	CC[C@H](N)C(=O)O	80283		BBB+	InChI=1S/C4H9NO2/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1		DrugBank	E	DrugBank
41		(5S)-5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione	CC[C@]1(C)OC(=O)N(C)C1=O	51380896		BBB+	InChI=1S/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3/t7-/m0/s1		DrugBank	E	DrugBank
42	CHLOROPROCAINE	2-(diethylamino)ethyl 4-amino-2-chlorobenzoate	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	8612		BBB+	InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3		DrugBank	E	DrugBank
43	SCHEMBL19420179	(5R)-5-[(2S)-hex-3-yn-2-yl]-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione	C=CC[C@@]1([C@@H](C)C#CCC)C(=O)NC(=O)N(C)C1=O	51397655		BBB+	InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)/t10-,14+/m0/s1		DrugBank	E	DrugBank
44	methysergide	(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide	CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1	9681		BBB+	InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1		DrugBank	E	DrugBank
45	CYTISINE	(1R,9S)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	O=c1cccc2n1C[C@@H]1CNC[C@H]2C1	10235		BBB+	InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m0/s1		DrugBank	E	DrugBank
46	CAPTODIAME, (R)-	2-[(R)-(4-butylsulfanylphenyl)-phenylmethyl]sulfanyl-N,N-dimethylethanamine	CCCCSc1ccc([C@H](SCCN(C)C)c2ccccc2)cc1	76959957		BBB+	InChI=1S/C21H29NS2/c1-4-5-16-23-20-13-11-19(12-14-20)21(24-17-15-22(2)3)18-9-7-6-8-10-18/h6-14,21H,4-5,15-17H2,1-3H3/t21-/m1/s1		DrugBank	E	DrugBank
47	ETHADIONE	3-ethyl-5,5-dimethyl-1,3-oxazolidine-2,4-dione	CCN1C(=O)OC(C)(C)C1=O	10630		BBB+	InChI=1S/C7H11NO3/c1-4-8-5(9)7(2,3)11-6(8)10/h4H2,1-3H3		DrugBank	E	DrugBank
48	PD133022	(2S)-N-carbamoyl-2-propan-2-ylpent-4-enamide	C=CC[C@H](C(=O)NC(N)=O)C(C)C	76961142		BBB+	InChI=1S/C9H16N2O2/c1-4-5-7(6(2)3)8(12)11-9(10)13/h4,6-7H,1,5H2,2-3H3,(H3,10,11,12,13)/t7-/m0/s1		DrugBank	E	DrugBank
49	METABUTETHAMINE	2-(2-methylpropylamino)ethyl 3-aminobenzoate	CC(C)CNCCOC(=O)c1cccc(N)c1	11115		BBB+	InChI=1S/C13H20N2O2/c1-10(2)9-15-6-7-17-13(16)11-4-3-5-12(14)8-11/h3-5,8,10,15H,6-7,9,14H2,1-2H3		DrugBank	E	DrugBank
50		ethyl 1-[(3S)-3-hydroxy-3-phenylpropyl]-4-phenylpiperidine-4-carboxylate	CCOC(=O)C1(c2ccccc2)CCN(CC[C@H](O)c2ccccc2)CC1	92215562		BBB+	InChI=1S/C23H29NO3/c1-2-27-22(26)23(20-11-7-4-8-12-20)14-17-24(18-15-23)16-13-21(25)19-9-5-3-6-10-19/h3-12,21,25H,2,13-18H2,1H3/t21-/m0/s1		DrugBank	E	DrugBank
51	citicoline	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate	C[N+](C)(C)CCO[P@](=O)([O-])O[P@@](=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O	13804		BBB+	InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/t9-,11-,12-,13-/m1/s1		DrugBank	E	DrugBank
52	citicoline	2-[[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxyethyl-trimethylazanium	C[N+](C)(C)CCO[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O	13805		BBB+	InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/p+1/t9-,11-,12-,13-/m1/s1		DrugBank	E	DrugBank
53	(R)-4-AMINO-3-PHENYLBUTANOIC ACID	(3R)-4-amino-3-phenylbutanoic acid	NC[C@H](CC(=O)O)c1ccccc1	685622		BBB+	InChI=1S/C10H13NO2/c11-7-9(6-10(12)13)8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H,12,13)/t9-/m0/s1		DrugBank	E	DrugBank
54	PD132851	(3R)-N-(4-ethoxyphenyl)-3-hydroxybutanamide	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1	6918884		BBB+	InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)/t9-/m1/s1		DrugBank	E	DrugBank
55	902HX6LS3B	(1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine	CCN[C@H]1[C@H]2CC[C@H](C2)[C@@H]1c1ccccc1	76960649		BBB+	InChI=1S/C15H21N/c1-2-16-15-13-9-8-12(10-13)14(15)11-6-4-3-5-7-11/h3-7,12-16H,2,8-10H2,1H3/t12-,13+,14+,15+/m1/s1		DrugBank	E	DrugBank
56	(+)-Phenazocine	(1S,9S,13S)-1,13-dimethyl-10-(2-phenylethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol	C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CCc1ccccc1	3048356		BBB+	InChI=1S/C22H27NO/c1-16-21-14-18-8-9-19(24)15-20(18)22(16,2)11-13-23(21)12-10-17-6-4-3-5-7-17/h3-9,15-16,21,24H,10-14H2,1-2H3/t16-,21+,22+/m1/s1		DrugBank	E	DrugBank
57	CHEMBL399122	2-[2-[4-[(2R)-2-methyl-3-phenothiazin-10-ylpropyl]piperazin-1-yl]ethoxy]ethanol	C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc21	9932302		BBB+	InChI=1S/C24H33N3O2S/c1-20(18-26-12-10-25(11-13-26)14-16-29-17-15-28)19-27-21-6-2-4-8-23(21)30-24-9-5-3-7-22(24)27/h2-9,20,28H,10-19H2,1H3/t20-/m1/s1		DrugBank	E	DrugBank
58		5-[(2R)-2-hydroxypropyl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione	C=CCC1(C[C@@H](C)O)C(=O)NC(=O)NC1=O	76968709		BBB+	InChI=1S/C10H14N2O4/c1-3-4-10(5-6(2)13)7(14)11-9(16)12-8(10)15/h3,6,13H,1,4-5H2,2H3,(H2,11,12,14,15,16)/t6-/m1/s1		DrugBank	E	DrugBank
59		(5S)-5-(2-bromoprop-2-enyl)-1-methyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione	C=C(Br)C[C@]1(C(C)C)C(=O)NC(=O)N(C)C1=O	76963951		BBB+	InChI=1S/C11H15BrN2O3/c1-6(2)11(5-7(3)12)8(15)13-10(17)14(4)9(11)16/h6H,3,5H2,1-2,4H3,(H,13,15,17)/t11-/m0/s1		DrugBank	E	DrugBank
60	WT 161;Reposal Novo	5-[(1R,5S)-3-bicyclo[3.2.1]oct-2-enyl]-5-ethyl-1,3-diazinane-2,4,6-trione	CCC1(C2=C[C@@H]3CC[C@H](C2)C3)C(=O)NC(=O)NC1=O	71307002		BBB+	InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)/t8-,9+/m1/s1		DrugBank	E	DrugBank
61	NS00068045	1,3-dimethyl-7-[2-[[(2R)-1-phenylpropan-2-yl]amino]ethyl]purine-2,6-dione	C[C@H](Cc1ccccc1)NCCn1cnc2c1c(=O)n(C)c(=O)n2C	25271663		BBB+	InChI=1S/C18H23N5O2/c1-13(11-14-7-5-4-6-8-14)19-9-10-23-12-20-16-15(23)17(24)22(3)18(25)21(16)2/h4-8,12-13,19H,9-11H2,1-3H3/t13-/m1/s1		DrugBank	E	DrugBank
62	PD132096	(2R,3R)-2-ethyl-3-methylpentanamide	CC[C@@H](C)[C@@H](CC)C(N)=O	36689722		BBB+	InChI=1S/C8H17NO/c1-4-6(3)7(5-2)8(9)10/h6-7H,4-5H2,1-3H3,(H2,9,10)/t6-,7-/m1/s1		DrugBank	E	DrugBank
63	Benorilate	(4-acetamidophenyl) 2-acetyloxybenzoate	CC(=O)Nc1ccc(OC(=O)c2ccccc2OC(C)=O)cc1	21102		BBB+	InChI=1S/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)		DrugBank	E	DrugBank
64	U3CV8K30PO	(2R)-N,N,2-trimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenyl)propan-1-amine	C[C@H](CC1c2ccccc2CCc2ccccc21)CN(C)C	36690126		BBB+	InChI=1S/C21H27N/c1-16(15-22(2)3)14-21-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)21/h4-11,16,21H,12-15H2,1-3H3/t16-/m1/s1		DrugBank	E	DrugBank
65	Butanilicaine	2-(butylamino)-N-(2-chloro-6-methylphenyl)acetamide	CCCCNCC(=O)Nc1c(C)cccc1Cl	22379		BBB+	InChI=1S/C13H19ClN2O/c1-3-4-8-15-9-12(17)16-13-10(2)6-5-7-11(13)14/h5-7,15H,3-4,8-9H2,1-2H3,(H,16,17)		DrugBank	E	DrugBank
66	Melevodopa	methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	23497		BBB+	InChI=1S/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1		DrugBank	E	DrugBank
67	(1S,2R)-2-phenylcyclopropanamine	(1S,2R)-2-phenylcyclopropan-1-amine	N[C@H]1C[C@@H]1c1ccccc1	26070		BBB+	InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m1/s1		DrugBank	E	DrugBank
68	BENZOCTAMINE	N-methyl-1-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)methanamine	CNC[C@]12CC[C@H](c3ccccc31)c1ccccc12	28425		BBB+	InChI=1S/C18H19N/c1-19-12-18-11-10-13(14-6-2-4-8-16(14)18)15-7-3-5-9-17(15)18/h2-9,13,19H,10-12H2,1H3/t13-,18-		DrugBank	E	DrugBank
69		3-(diethylamino)propyl (1S,2S,4R)-2-phenylbicyclo[2.2.1]heptane-2-carboxylate	CCN(CC)CCCOC(=O)[C@@]1(c2ccccc2)C[C@@H]2CC[C@H]1C2	76965001		BBB+	InChI=1S/C21H31NO2/c1-3-22(4-2)13-8-14-24-20(23)21(18-9-6-5-7-10-18)16-17-11-12-19(21)15-17/h5-7,9-10,17,19H,3-4,8,11-16H2,1-2H3/t17-,19+,21-/m1/s1		DrugBank	E	DrugBank
70	Levlofexidine	2-[(1R)-1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1	3038503		BBB+	InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)/t7-/m1/s1		DrugBank	E	DrugBank
71	DEXETIMIDE	(3S)-3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione	O=C1CC[C@@](c2ccccc2)(C2CCN(Cc3ccccc3)CC2)C(=O)N1	30843		BBB+	InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m1/s1		DrugBank	E	DrugBank
72	PARALDEHYDE	2,4,6-trimethyl-1,3,5-trioxane	C[C@H]1O[C@@H](C)O[C@@H](C)O1	31264		BBB+	InChI=1S/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3/t4-,5+,6-		DrugBank	E	DrugBank
73	Articaine, (S)-	methyl 4-methyl-3-[[(2S)-2-(propylamino)propanoyl]amino]thiophene-2-carboxylate	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC	6604377		BBB+	InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)/t9-/m0/s1		DrugBank	E	DrugBank
74	OXETORONE	3-(12H-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-N,N-dimethylpropan-1-amine	CN(C)CCC=C1c2ccccc2OCc2c1oc1ccccc21	36846		BBB+	InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3		DrugBank	E	DrugBank
75	NCGC00183654-01	(2S)-N-(2,6-dimethylphenyl)-2-[ethyl(propyl)amino]butanamide	CCCN(CC)[C@@H](CC)C(=O)Nc1c(C)cccc1C	12862484		BBB+	InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)/t15-/m0/s1		DrugBank	E	DrugBank
76	QCE81YBK8Q	(3R)-7-chloro-5-(2-fluorophenyl)-3-hydroxy-1-(2-hydroxyethyl)-3H-1,4-benzodiazepin-2-one	O=C1[C@@H](O)N=C(c2ccccc2F)c2cc(Cl)ccc2N1CCO	76967234		BBB+	InChI=1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2/t16-/m1/s1		DrugBank	E	DrugBank
77	Progabide	4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide	NC(=O)CCC/N=C(\c1ccc(Cl)cc1)c1cc(F)ccc1O	44115		BBB+	InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,22H,1-2,9H2,(H2,20,23)/b21-17+		DrugBank	E	DrugBank
78	Ethallobarbital	5-ethyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione	C=CCC1(CC)C(=O)NC(=O)NC1=O	48542		BBB+	InChI=1S/C9H12N2O3/c1-3-5-9(4-2)6(12)10-8(14)11-7(9)13/h3H,1,4-5H2,2H3,(H2,10,11,12,13,14)		DrugBank	E	DrugBank
79	Rotigotine	(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	59227		BBB+	InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3/t16-/m0/s1		DrugBank	E	DrugBank
80	BEZITRAMIDE	4-[4-(2-oxo-3-propanoylbenzimidazol-1-yl)piperidin-1-yl]-2,2-diphenylbutanenitrile	CCC(=O)n1c(=O)n(C2CCN(CCC(C#N)(c3ccccc3)c3ccccc3)CC2)c2ccccc21	61791		BBB+	InChI=1S/C31H32N4O2/c1-2-29(36)35-28-16-10-9-15-27(28)34(30(35)37)26-17-20-33(21-18-26)22-19-31(23-32,24-11-5-3-6-12-24)25-13-7-4-8-14-25/h3-16,26H,2,17-22H2,1H3		DrugBank	E	DrugBank
81		[(3S)-3,6-dihydroxy-1-propan-2-yl-2,3-dihydroindol-5-yl]iminourea	CC(C)N1C[C@@H](O)c2cc(/N=N/C(N)=O)c(O)cc21	135565885		BBB+	InChI=1S/C12H16N4O3/c1-6(2)16-5-11(18)7-3-8(14-15-12(13)19)10(17)4-9(7)16/h3-4,6,11,17-18H,5H2,1-2H3,(H2,13,19)/b15-14+/t11-/m1/s1		DrugBank	E	DrugBank
82		(1S)-2-[bis[(2R)-butan-2-yl]amino]-1-[1-[(2-chlorophenyl)methyl]pyrrol-2-yl]ethanol	CC[C@@H](C)N(C[C@H](O)c1cccn1Cc1ccccc1Cl)[C@H](C)CC	76961195		BBB+	InChI=1S/C21H31ClN2O/c1-5-16(3)24(17(4)6-2)15-21(25)20-12-9-13-23(20)14-18-10-7-8-11-19(18)22/h7-13,16-17,21,25H,5-6,14-15H2,1-4H3/t16-,17-,21+/m1/s1		DrugBank	E	DrugBank
83	Chlorproethazine	3-(2-chlorophenothiazin-10-yl)-N,N-diethylpropan-1-amine	CCN(CC)CCCN1c2ccccc2Sc2ccc(Cl)cc21	65750		BBB+	InChI=1S/C19H23ClN2S/c1-3-21(4-2)12-7-13-22-16-8-5-6-9-18(16)23-19-11-10-15(20)14-17(19)22/h5-6,8-11,14H,3-4,7,12-13H2,1-2H3		DrugBank	E	DrugBank
84	Dipyrocetyl	2,3-diacetyloxybenzoic acid	CC(=O)Oc1cccc(C(=O)O)c1OC(C)=O	68093		BBB+	InChI=1S/C11H10O6/c1-6(12)16-9-5-3-4-8(11(14)15)10(9)17-7(2)13/h3-5H,1-2H3,(H,14,15)		DrugBank	E	DrugBank
85	Guacetisal	(2-methoxyphenyl) 2-acetyloxybenzoate	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	68749		BBB+	InChI=1S/C16H14O5/c1-11(17)20-13-8-4-3-7-12(13)16(18)21-15-10-6-5-9-14(15)19-2/h3-10H,1-2H3		DrugBank	E	DrugBank
86	Acamprosate	3-acetamidopropane-1-sulfonic acid	CC(=O)NCCCS(=O)(=O)O	71158		BBB+	InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)		DrugBank	E	DrugBank
87		N-[(2R)-4-[4-(4-fluorophenyl)piperazin-1-yl]butan-2-yl]pyridine-3-carboxamide	C[C@H](CCN1CCN(c2ccc(F)cc2)CC1)NC(=O)c1cccnc1	76956128		BBB+	InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)/t16-/m1/s1		DrugBank	E	DrugBank
88		ethyl (6S)-1,6-dimethyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-1-ium-3-carboxylate	CCOC(=O)c1c[n+](C)c2n(c1=O)[C@@H](C)CCC2	15584873		BBB+	InChI=1S/C13H19N2O3/c1-4-18-13(17)10-8-14(3)11-7-5-6-9(2)15(11)12(10)16/h8-9H,4-7H2,1-3H3/q+1/t9-/m0/s1		DrugBank	E	DrugBank
89	Frovatriptan	(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide	CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1	77992		BBB+	InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1		DrugBank	E	DrugBank
90	Agomelatine	N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide	COc1ccc2cccc(CCNC(C)=O)c2c1	82148		BBB+	InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)		DrugBank	E	DrugBank
91	Cevimeline	(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]	C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1	83898		BBB+	InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1		DrugBank	E	DrugBank
92		11-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-5,6-dihydrobenzo[b][1]benzazepine	c1ccc2c(c1)CCc1ccccc1N2[C@H]1CN2CCC1CC2	76957954		BBB+	InChI=1S/C21H24N2/c1-3-7-19-16(5-1)9-10-17-6-2-4-8-20(17)23(19)21-15-22-13-11-18(21)12-14-22/h1-8,18,21H,9-15H2/t21-/m0/s1		DrugBank	E	DrugBank
93	Tirilazad	(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1	104903		BBB+	InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1		DrugBank	E	DrugBank
94	Mebicar	1,3,4,6-tetramethyl-3a,6a-dihydroimidazo[4,5-d]imidazole-2,5-dione	CN1C(=O)N(C)[C@H]2[C@@H]1N(C)C(=O)N2C	122282		BBB+	InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3/t5-,6+		DrugBank	E	DrugBank
95	142761-11-3	4-[(1R)-2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1	12018336		BBB+	InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3/t15-/m0/s1		DrugBank	E	DrugBank
96	Safinamide	(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	131682		BBB+	InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1		DrugBank	E	DrugBank
97	Scopace	[(1R,2R,4S,5S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate	CN1[C@@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12	3000322		BBB+	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13+,14-,15+,16-/m1/s1		DrugBank	E	DrugBank
98	Varenicline	(1R,12S)-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene	c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1	5310966		BBB+	InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+		DrugBank	E	DrugBank
99	Ropivacaine	(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	175805		BBB+	InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1		DrugBank	E	DrugBank
100	Tropatepine	(1S,5R)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-8-methyl-8-azabicyclo[3.2.1]octane	CN1[C@@H]2CC[C@H]1CC(=C1c3ccccc3CSc3ccccc31)C2	3034047		BBB+	InChI=1S/C22H23NS/c1-23-17-10-11-18(23)13-16(12-17)22-19-7-3-2-6-15(19)14-24-21-9-5-4-8-20(21)22/h2-9,17-18H,10-14H2,1H3/t17-,18+		DrugBank	E	DrugBank
101	Lurasidone	(1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione	O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1	213046		BBB+	InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1		DrugBank	E	DrugBank
102	Lacosamide	(2R)-2-acetamido-N-benzyl-3-methoxypropanamide	COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1	219078		BBB+	InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1		DrugBank	E	DrugBank
103	Phenazocine, (-)-	(1R,9R,13R)-1,13-dimethyl-10-(2-phenylethyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol	C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCc1ccccc1	443405		BBB+	InChI=1S/C22H27NO/c1-16-21-14-18-8-9-19(24)15-20(18)22(16,2)11-13-23(21)12-10-17-6-4-3-5-7-17/h3-9,15-16,21,24H,10-14H2,1-2H3/t16-,21+,22+/m0/s1		DrugBank	E	DrugBank
104	cocaine	methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate	COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C	446220		BBB+	InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1		DrugBank	E	DrugBank
105	Ipidacrine	2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine	Nc1c2c(nc3c1CCC3)CCCC2	604519		BBB+	InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)		DrugBank	E	DrugBank
106	scopolamine	[(1S,2R,4S,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2R)-3-hydroxy-2-phenylpropanoate	CN1[C@@H]2C[C@H](OC(=O)[C@@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@H]12	638340		BBB+	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13+,14-,15-,16+/m0/s1		DrugBank	E	DrugBank
107	cannabidiol	2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol	C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O	644019		BBB+	InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1		DrugBank	E	DrugBank
108	Choline Alfoscerate	[(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate	C[N+](C)(C)CCO[P@](=O)([O-])OC[C@H](O)CO	657272		BBB+	InChI=1S/C8H20NO6P/c1-9(2,3)4-5-14-16(12,13)15-7-8(11)6-10/h8,10-11H,4-7H2,1-3H3/t8-/m1/s1		DrugBank	E	DrugBank
109	CYTISINE	(1S,9R)-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one	O=c1cccc2n1C[C@H]1CNC[C@@H]2C1	683511		BBB+	InChI=1S/C11H14N2O/c14-11-3-1-2-10-9-4-8(5-12-6-9)7-13(10)11/h1-3,8-9,12H,4-7H2/t8-,9+/m1/s1		DrugBank	E	DrugBank
110	benztropine	(1S,5R)-3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane	CN1[C@@H]2CC[C@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2	1201549		BBB+	InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20-		DrugBank	E	DrugBank
111	Adrafinil, (R)-	2-[(R)-benzhydrylsulfinyl]-N-hydroxyacetamide	O=C(C[S@@](=O)C(c1ccccc1)c1ccccc1)NO	25271624		BBB+	InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17)/t20-/m1/s1		DrugBank	E	DrugBank
112	Asenapine	(2R,6R)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene	CN1C[C@H]2c3ccccc3Oc3ccc(Cl)cc3[C@@H]2C1	3036780		BBB+	InChI=1S/C17H16ClNO/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19/h2-8,14-15H,9-10H2,1H3/t14-,15-/m0/s1		DrugBank	E	DrugBank
113		(2S)-2-amino-5-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)pentanoic acid	N[C@@H](CCCN1C(=O)NC(c2ccccc2)(c2ccccc2)C1=O)C(=O)O	93482134		BBB+	InChI=1S/C20H21N3O4/c21-16(17(24)25)12-7-13-23-18(26)20(22-19(23)27,14-8-3-1-4-9-14)15-10-5-2-6-11-15/h1-6,8-11,16H,7,12-13,21H2,(H,22,27)(H,24,25)/t16-/m0/s1		DrugBank	E	DrugBank
114	Tolcapone	(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone	Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1	4659569		BBB+	InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3		DrugBank	E	DrugBank
115	Istradefylline	8-[(E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methylpurine-2,6-dione	CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O	5311037		BBB+	InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+		DrugBank	E	DrugBank
116	DEXMEDETOMIDINE	5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole	Cc1cccc([C@H](C)c2cnc[nH]2)c1C	5311068		BBB+	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1		DrugBank	E	DrugBank
117	(+)-Stiripentol	(E,3R)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol	CC(C)(C)[C@H](O)/C=C/c1ccc2c(c1)OCO2	38988294		BBB+	InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+/t13-/m1/s1		DrugBank	E	DrugBank
118	OXETORONE	(3E)-3-(12H-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-N,N-dimethylpropan-1-amine	CN(C)CC/C=C1\c2ccccc2OCc2c1oc1ccccc21	6434185		BBB+	InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3/b17-10+		DrugBank	E	DrugBank
119	OXETORONE	(3Z)-3-(12H-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-N,N-dimethylpropan-1-amine	CN(C)CC/C=C1/c2ccccc2OCc2c1oc1ccccc21	6436540		BBB+	InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3/b17-10-		DrugBank	E	DrugBank
120	Carisbamate	[(2S)-2-(2-chlorophenyl)-2-hydroxyethyl] carbamate	NC(=O)OC[C@@H](O)c1ccccc1Cl	6918474		BBB+	InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1		DrugBank	E	DrugBank
121	Acetyl-L-carnitine	(3R)-3-acetyloxy-4-(trimethylazaniumyl)butanoate	CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C	7045767		BBB+	InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m1/s1		DrugBank	E	DrugBank
122	Brivaracetam	(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide	CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1	9837243		BBB+	InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1		DrugBank	E	DrugBank
123	Tapentadol	3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol	CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C	9838022		BBB+	InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1		DrugBank	E	DrugBank
124	Fabomotizole	4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	9862937		BBB+	InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)		DrugBank	E	DrugBank
125	Remimazolam	methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21	9867812		BBB+	InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1		DrugBank	E	DrugBank
126	Eslicarbazepine	(5S)-5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide	NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21	9881504		BBB+	InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1		DrugBank	E	DrugBank
127	scopolamine	[(1S,2R,4S,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate	CN1[C@@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@H]12	3081743		BBB+	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13+,14-,15-,16+/m1/s1		DrugBank	E	DrugBank
128	Perampanel	2-(2-oxo-1-phenyl-5-pyridin-2-ylpyridin-3-yl)benzonitrile	N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O	9924495		BBB+	InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H		DrugBank	E	DrugBank
129	Pitolisant	1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine	Clc1ccc(CCCOCCCN2CCCCC2)cc1	9948102		BBB+	InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2		DrugBank	E	DrugBank
130	VORTIOXETINE	1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	9966051		BBB+	InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3		DrugBank	E	DrugBank
131	Pimavanserin	1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	10071196		BBB+	InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)		DrugBank	E	DrugBank
132	Solriamfetol	[(2R)-2-amino-3-phenylpropyl] carbamate	NC(=O)OC[C@H](N)Cc1ccccc1	10130337		BBB+	InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1		DrugBank	E	DrugBank
133	Tasimelteon	N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2	10220503		BBB+	InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1		DrugBank	E	DrugBank
134	Cariprazine	3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea	CN(C)C(=O)N[C@H]1CC[C@@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1	11154555		BBB+	InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17+		DrugBank	E	DrugBank
135	Lisdexamfetamine	(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide	C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN	11597698		BBB+	InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1		DrugBank	E	DrugBank
136	Cenobamate	[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate	NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	11962412		BBB+	InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1		DrugBank	E	DrugBank
137	BREXPIPRAZOLE	7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one	O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1	11978813		BBB+	InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)		DrugBank	E	DrugBank
138	(-)-tilidine	ethyl (1R,2S)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate	CCOC(=O)[C@@]1(c2ccccc2)CCC=C[C@@H]1N(C)C	12546498		BBB+	InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m0/s1		DrugBank	E	DrugBank
139	Cevimeline	(2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]	C[C@H]1O[C@]2(CS1)CN1CCC2CC1	18642481		BBB+	InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m0/s1		DrugBank	E	DrugBank
140	Ethybenztropine	(1R,5S)-3-benzhydryloxy-8-ethyl-8-azabicyclo[3.2.1]octane	CCN1[C@@H]2CC[C@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2	20055089		BBB+	InChI=1S/C22H27NO/c1-2-23-19-13-14-20(23)16-21(15-19)24-22(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12,19-22H,2,13-16H2,1H3/t19-,20+,21-		DrugBank	E	DrugBank
141	Flumedroxone	(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-6-(trifluoromethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C(F)(F)F)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C	20055352		BBB+	InChI=1S/C22H29F3O3/c1-12(26)21(28)9-6-16-14-11-18(22(23,24)25)17-10-13(27)4-7-19(17,2)15(14)5-8-20(16,21)3/h10,14-16,18,28H,4-9,11H2,1-3H3/t14-,15+,16+,18+,19-,20+,21+/m1/s1		DrugBank	E	DrugBank
142	Valbenazine	[(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate	COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2	24795069		BBB+	InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1		DrugBank	E	DrugBank
143	Suvorexant	[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone	Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1	24965990		BBB+	InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1		DrugBank	E	DrugBank
144	CDP-choline(1-)	[[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate	C[N+](C)(C)CCO[P+]([O-])([O-])O[P+]([O-])([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O	25202509		BBB+	InChI=1S/C14H26N4O11P2/c1-18(2,3)6-7-26-30(22,23)29-31(24,25)27-8-9-11(19)12(20)13(28-9)17-5-4-10(15)16-14(17)21/h4-5,9,11-13,19-20H,6-8H2,1-3H3,(H3-,15,16,21,22,23,24,25)/p-1/t9-,11-,12-,13-/m1/s1		DrugBank	E	DrugBank
145	Laquinimod	5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	54677946		BBB+	InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3		DrugBank	E	DrugBank
146	Mirogabalin	2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid	CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O	59509752		BBB+	InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1		DrugBank	E	DrugBank
147	Mazaticol	[(1S,3S,5S)-6,6,9-trimethyl-9-azabicyclo[3.3.1]nonan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate	CN1[C@H]2CCC(C)(C)[C@@H]1C[C@@H](OC(=O)C(O)(c1cccs1)c1cccs1)C2	90471539		BBB+	InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16-/m0/s1		DrugBank	E	DrugBank
148	Mazaticol	[(1R,3R,5S)-6,6,9-trimethyl-9-azabicyclo[3.3.1]nonan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate	CN1[C@@H]2CCC(C)(C)[C@@H]1C[C@H](OC(=O)C(O)(c1cccs1)c1cccs1)C2	118984411		BBB+	InChI=1S/C21H27NO3S2/c1-20(2)9-8-14-12-15(13-16(20)22(14)3)25-19(23)21(24,17-6-4-10-26-17)18-7-5-11-27-18/h4-7,10-11,14-16,24H,8-9,12-13H2,1-3H3/t14-,15-,16+/m1/s1		DrugBank	E	DrugBank
149	R-Etifoxine	(4R)-6-chloro-N-ethyl-4-methyl-4-phenyl-1H-3,1-benzoxazin-2-imine	CC/N=C1\Nc2ccc(Cl)cc2[C@@](C)(c2ccccc2)O1	135564606		BBB+	InChI=1S/C17H17ClN2O/c1-3-19-16-20-15-10-9-13(18)11-14(15)17(2,21-16)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3,(H,19,20)/t17-/m1/s1		DrugBank	E	DrugBank
150	Opicapone	5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1	135565903		BBB+	InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3		DrugBank	E	DrugBank
151	Mepyramine	N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	4992		BBB+	InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
152	Rotoxamine	2-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1	170336		BBB+	InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3/t16-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
153	UNII-FF3207A72P	(2S)-N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc21	6604496		BBB+	InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3/t14-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
154	Lopac-P-6902	(3S)-N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine	CN(C)CC[C@@H](c1ccccc1)c1ccccn1	667440		BBB+	InChI=1S/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3/t15-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
155	Cyclizine	1-benzhydryl-4-methylpiperazine	CN1CCN(C(c2ccccc2)c2ccccc2)CC1	6726		BBB+	InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
156	Chlorcyclizine, (R)-	1-[(R)-(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine	CN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1	688438		BBB+	InChI=1S/C18H21ClN2/c1-20-11-13-21(14-12-20)18(15-5-3-2-4-6-15)16-7-9-17(19)10-8-16/h2-10,18H,11-14H2,1H3/t18-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
157	(R)-Meclizine	1-[(R)-(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine	Cc1cccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1	23307231		BBB+	InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3/t25-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
158	Diphenhydramine	2-benzhydryloxy-N,N-dimethylethanamine	CN(C)CCOC(c1ccccc1)c1ccccc1	3100		BBB+	InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
159	Dexbrompheniramine	(3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1	16960		BBB+	InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
160	Chloropyramine	N'-[(4-chlorophenyl)methyl]-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	25295		BBB+	InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
161	UNII-WC177DTO9Q	N,N-dimethyl-2-[(1R)-1-phenyl-1-pyridin-2-ylethoxy]ethanamine	CN(C)CCO[C@](C)(c1ccccc1)c1ccccn1	6852255		BBB+	InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3/t17-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
162	Tripelennamine	N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine	CN(C)CCN(Cc1ccccc1)c1ccccn1	5587		BBB+	InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
163	R-dimethindene	N,N-dimethyl-2-[3-[(1R)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine	C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1	12963076		BBB+	InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3/t15-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
164	Cyproheptadine	1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine	CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1	2913		BBB+	InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
165	Antazoline	N-benzyl-N-(4,5-dihydro-1H-imidazol-2-ylmethyl)aniline	c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1	2200		BBB+	InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
166	Dexchlorpheniramine	(3S)-3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	33036		BBB+	InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
167	Clemastine	(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	26987		BBB+	InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
168	R-Hydroxyzine	2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol	OCCOCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1	1548974		BBB+	InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2/t21-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
169	Lopac-O-3752	N,N-dimethyl-2-[(S)-(2-methylphenyl)-phenylmethoxy]ethanamine	Cc1ccccc1[C@@H](OCCN(C)C)c1ccccc1	736041		BBB+	InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3/t18-/m0/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
170	(R)-bromazine	2-[(R)-(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine	CN(C)CCO[C@H](c1ccccc1)c1ccc(Br)cc1	45266805		BBB+	InChI=1S/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3/t17-/m1/s1		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
171	Triprolidine	2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine	Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1	5282443		BBB+	InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+		(1) Simon, F. E. R.; Simons, K. J. H1 Antihistamines: Current Status and Future Directions. World Allergy Organization Journal 2008, 1 (9), 145–155. (2) Tamai, I.; Kido, Y.; Yamashita, J.; Sai, Y.; Tsuji, A. Blood-Brain Barrier Transport of H1-Antagonist Ebastine and Its Metabolite Carebastine. Journal of Drug Targeting 2000, 8 (6), 383–393. (3) YAMAZAKI, M.; FUKUOKA, H.; NAGATA, O.; KATO, H.; ITO, Y.; TERASAKI, T.; TSUJI, A. Transport Mechanism of an H1-Antagonist at the Blood-Brain Barrier: Transport Mechanism of Mepyramine Using the Carotid Injection Technique. Biological and Pharmaceutical Bulletin 1994, 17 (5), 676–679.	E	
172	Tarenflurbil	(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid	Fc2cc(ccc2c1ccccc1)[C@H](C(=O)O)C	92337		BBB-	InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1		Imbimbo, B. P. Why Did Tarenflurbil Fail in Alzheimer’s Disease? Journal of Alzheimer’s Disease 2009, 17 (4), 757–760.	E	At proposed therapeutic concentrations, this molecule lacks anti-inflammatory activity, and does not inhibit either cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2) enzymes.
173	Gavestinel	3-[(E)-3-anilino-3-oxoprop-1-enyl]-4,6-dichloro-1H-indole-2-carboxylic acid	OC(C1=C(/C=C/C(NC2=CC=CC=C2)=O)C3=C(Cl)C=C(Cl)C=C3N1)=O	6450546		BBB-	InChI=1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+		(1) Sacco, R. L.; DeRosa, J. T.; Haley, Jr, E. C.; Levin, B.; Ordronneau, P.; Phillips, S. J.; Rundek, T.; Snipes, R. G.; Thompson, J. L. P.; for the GAIN Americas Investigators. Glycine Antagonist in Neuroprotection for Patients with Acute Stroke. JAMA 2001, 285 (13), 1719. (2) Alavijeh, M. S.; Chishty, M.; Qaiser, M. Z.; Palmer, A. M. Drug Metabolism and Pharmacokinetics, the Blood-Brain Barrier, and Central Nervous System Drug Discovery. NeuroRX 2005, 2 (4), 554–571.	E	Gavestinel, which reached Phase III clinical trials but did not show clear effectiveness, likely due to its inability to cross the BBB
174	dopamine	4-(2-aminoethyl)benzene-1,2-diol	NCCc1cc(O)c(O)cc1	681		BBB-	InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2		Ahlskog, J. E. Common Myths and Misconceptions That Sidetrack Parkinson Disease Treatment, to the Detriment of Patients. Mayo Clinic Proceedings 2020, 95 (10), 2225–2234.	E	Cannot cross the BBB when administered peripherally, preventing CNS delivery
175	paclitaxel	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate	CC1=C2[C@@]([C@]([C@H]([C@@H]3[C@]4([C@H](OC4)C[C@@H]([C@]3(C(=O)[C@@H]2OC(=O)C)C)O)OC(=O)C)OC(=O)c5ccccc5)(C[C@@H]1OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)O)(C)C	36314		BBB-	InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1		Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhänel, M.; Spruss, T.; Bernhardt, G.; Graeff, C.; Färber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of Paclitaxel (Taxol) across the Blood-Brain Barrier in Vitro and in Vivo. The Journal of Clinical Investigation 2002, 110 (9), 1309–1318. 	E	

